newsfilter
← Latest News
Earnings Call Transcripts·

OCSL 4Q2026 Earnings Call - OAKTREE SPECIALTY LENDING CORP

Welcome, and thank you for joining Oaktree Specialty Lending Corporation's 4th Fiscal Quarter 2026 Conference Call. Today's conference is being recorded. After today's prepared remarks, we will host a question and answer session. If you would like to ask a question, please press star 1 to raise your hand. To withdraw your question, press star 2 to raise hand. Press star 1 again. I will now turn the call over to Allison Murray, OCSL's Head of Investor Relations. Please go ahead. Thank you, Operator. Our fourth fiscal quarter and full year 2026 earnings release, which we issued this morning, along with the accompanying slide presentation, can be accessed on the Investor section of our website, OaktreeSpecialtyLending.com. Before we begin, I want to remind you that the comments on today's call include forward-looking statements reflecting current views with respect to, among other things, future operating results and financial performance. Actual results could differ materially from those implied or expressed in the forward- looking statement. Please refer to the relevant SEC filings for a discussion of these factors in further detail. Oaktree undertakes no duty to update or revise any forward-lookings statements. I'd also like to remind you that nothing on this call constitutes an offer to sell or solicitation of an offer to purchase any interest in an Oak Tree Fund. Investors and others should note that OCSL uses the investor section of its corporate website to announce material information. The company encourages investors, the media, and others to review information that it shares on its website. On today's call, Matt Pendo, President of OCS, will begin with a progress report on fiscal 2026 priorities and an overview of our fourth fiscal quarter results. Armin Panossian, CEO and Co-Chief Investment Officer will then provide a market update. Rob Vapkhana, Co-Chef Investment Officer will cover portfolio activity. And Chris McCown, CFO and Treasurer will close with a review of our financial results before we open the call for questions. Now I'll turn the call over to Matt Pendo, President of OCSL. Matt. Thank you, Allison, and good morning, everyone. I would like to begin by reflecting on the progress we've made against our two main priorities from this past year. Number one, reducing non-accruals, and number two, keeping our balance sheet flexible. I'll then cover our financial highlights and our dividends, starting with non- accruals. At the end of our fiscal year, non- Accruals were approximately 1.8% of the total debt portfolio at fair value. This was down about 120 basis points from a year ago and relatively unchanged from June. In dollar terms, non-accruals at fair value have fallen from $81 million a year ago to $45 million today, a reduction of 44%. Importantly, nearly 85% of the decline in non- accrual dollars over the past year came from proceeds received and investments returning to accrual status. We believe this reflects our team's ability to successfully work through challenging credits. Raghav will walk through additional updates to non-accrual positions in his remarks. There were several positive developments to our balance sheet this quarter, including an update to our ratings outlook and a bond offering. First, in August, Moody's revised our outlook to stable and kept our BAA3 rating unchanged. Second, in September, we priced $300 million of five-year unsecured notes due 2031 with a 7% coupon and a spread of 240 basis points over U.S. Treasury. After swapping the floating rate, the equivalent spread to SOFR is 258 basis points. This was our first bond issuance in over a year, and we were pleased with the outcome in a choppy market backdrop. Demand was strong with the final order book more than three times the size of the deal and included new OCSL bond investors. We want to thank the fixed income community for their support on this transaction. The incremental cost of the new financing is less than half a cent per share per quarter. After the January 2027 notes of repaid maturity using borrowings under our revolving credit facility, we'll be left with a well-staggered maturity profile and our next debt maturity is February 2029. We maintain conservative leverage during the quarter, ending September 30th at 1.00 net debt to equity. Over the course of fiscal year 2026, we maintain net leverage between 0.97 times and 1.07 times, well inside the long-term target range of 0.9 times to 1.25 times. Liquidity was approximately $1.04 billion a quarter in. That figure is temporarily elevated because the January notes have not yet been repaid. Proforma for that repayment, liquidity is approximately $689 million in line with last quarter and a year ago. Turning to financial highlights for our fourth fiscal quarter and fiscal year. Adjusted net investment income was $29.6 million, or approximately $0.34 per share, down from $32.2 million, for $0,037 per share in the prior quarter. This decrease primarily reflected a lower average portfolio balance and a higher income-based incentive fee. For the full fiscal year, adjusted net investment outcome was $131.7 million, or $1.49 per share, compared to $151.3 million or $176 per share for the 2025 fiscal year. Now turning to the dividends. Our board declared a total cash dividend of $0.32 per share for the quarter, composed of a base cash dividend $0,30 per share and a supplemental dividend of $0.02 per share. The dividends are payable in cash on December 31, 2026. The stock hold is a record on December 15, 2027. As a reminder, we adjusted the base dividend in May to be covered by earnings at our current conservative leverage and maintain the supplemental dividend equal to 50% of adjusted net investment income in excess of the base dividends. Dividends declared in fiscal 2026 totaled $1.39 per share, which represented 108% of adjusted net investment income. As we look to fiscal 2027, our top priorities are unchanged. Resolve non-accruals, exit non-income producing equity positions, and redeploy those proceeds into performing assets. With net leverage of 1.00 times and nearly $700 million of pro forma liquidity, we have the flexibility to be opportunistic as new investments and strategic opportunities arise. With that, I'll turn the call over to Armin to discuss the market environment. Thank you, Matt. Since this is a fiscal year-end call, I want to compare where we stood a year ago with where we are today. Last year, the Fed had just cut rates in September and October, and the market expected additional rate cuts in 2026, along with an upswing in M&A activity. Neither of those predictions materialized. Instead, markets saw increased volatility in early 2026 amid concerns of AI disruption, geopolitical uncertainty, and renewed inflation pressures. It's a good reminder of why Oak Tree's investment philosophy is tied to fundamental credit analysis rather than macro forecasting. Fast forward to today. With Brent crude rising above $100 per barrel during the September quarter and large AI-related capex adding to inflation pressures, the Fed instead raised rates by 25 basis points. That put the federal funds rate at 3.75 to 4%, and the 10-year treasury yield moved above the symbolic 5% threshold, reaching its highest level in nearly two decades. A year ago, the debate was how far rates would fall. Today, it is how long they stay high and how high. Our view is that a move in short-term base rates from approximately 4% to 5% would remain manageable and could be beneficial to investor returns, as most of the increase would flow through to net investment income. For OCSL, 91% of our debt investments are floating rate, and a higher base rate increases contractual interest income as loans reset. The other important factor is whether our borrowers can withstand higher rates. We assess each borrower's interest coverage across a range of base rate scenarios and build cushion into the capital structure at underwriting. Based on our borrowers' last 12 months of results, weighted average interest coverage is 2.3 times. If base rates rose by 100 basis points, coverage would still be about 2.1 times above the roughly 1.9 times trough our portfolio experienced in late 2023 and early 2024. Against the change in the rate backdrop, credit market outcomes in the quarter were uneven. U.S. lovers' loans returned nearly 2%, supported by floating rate coupons that limit sensitivity to rising rates, while high-yield bonds declined by almost 2% as Treasury yields rose. Corporate fundamentals remained broadly resilient, but the weakest leverage credits lagged, reflecting increasingly selective investor appetite and the growing strain of elevated borrowing costs. On deal activity, direct lending volume rebounded slightly in September, although year-to-date deal flow and average deal size remained below that of last year. Capital is still competitive for most transactions, despite a pullback from many of the largest non-traded VECs, meaning supply and demand are relatively balanced. Spreads on new sponsor-backed first lien loans held at SOFR plus 500 to 550 basis points for several months, about 50 to 100 basis points wider than that at the end of 2025 as the broadly syndicated loan market continued to tighten in the quarter the premium that direct lending new originations offered over new broadly syndicated loans widened to over 150 basis points putting it together we remain focused on what we can control and we feel well positioned even in a higher for longer and more volatile environment With that, I will turn the call over to Raghav for a review of our investment activity and portfolio. Thank you, Armin. I'll start with new originations and exits, then discuss non-accruals before closing with portfolio metrics. Turning to originations, new investment commitments total $179 million in the quarter, compared with $206 million last quarter and $208 million inthe fourth fiscal quarter of 2025. We have seen our pipeline build steadily since late September and originated about $80 million of new investment commitments in October. Weighted average yield on new debt investments during the quarter was 9.6%, with a spread on new originations of about 570 basis points, wider than the market spread range of 500 to 550. notable deal during the quarter was a first lien loan to Outcomes First Group, which appears as OSS Bitco on our schedule of investments. Outcomes first group is the UK's largest independent provider of schools for children and youth with special educational needs and disabilities. The total facility consisted of 600 million pounds of first lien debt with about 75% than funded upfront, priced at SONIA plus 525 basis points with 1.5 points of OID. The transaction refinanced the company's existing debt and supports further expansion, including internationally. Oaktree's longstanding relationship with the sponsor, PPG, positioned Oaktre as the anchor lender. The investment was underwritten and structured by our European private debt team that has deep local market knowledge and direct engagement with the management team. We like the company due to its long operating history, hard-to-replicate footprint, high quality of schools, and strong revenue visibility. It also operates in an industry with several demand tailwinds that includes statutory funding obligations a persistent structural supply shortage and high barriers to entry this deal demonstrates the value of combining on-the-ground presence and regional expertise with global relationships during the quarter we also participated in three performing equity investments that increased our equity exposure to 5.5 percent of fair value from 3.9 percent last quarter. These income-producing equity deals are highly structured with negotiated downside protection and offer compelling risk-adjusted returns for our portfolio. Moving now to exits and prepayments. Proceeds from prepayment exits, other paydowns, and sales were $198 million compared with $263 million last quarter and $177 million last year. We were repaid in full on several private investments during the quarter. Some borrowers were taken out in the broadly syndicated loan market, and some were refinanced by other private lenders. A notable exit in the quarter was the repayment of our first lean term loan in RumbleOn, which appeared in our schedule of investments as RightNow Group, a publicly traded company that operates power sports retail dealerships and an e-commerce business. We were the agent on the term loan, which originally funded in 2021 to finance Rumble On's acquisition of the RightNow Power Sports platform. Integration challenges and weaker post-COVID consumer spending pressured EBITDA and put covenant compliance at risk, leading us to mark the loan down to 94 in the year 2023. Importantly, our highly structured loan prevented value leakage during the company's period of underperformance and we worked collaboratively with the company on a turnaround plan involving new management, cost reductions, asset sales, and capital raises. These actions repositioned the company for growth and we were willing to provide relief to the company in the form of covenant resets and a maturity extension in exchange for debt paydowns during this time to right-size the balance sheet. In September, RumbleOn refinanced its term loan and our remaining $35 million position was repaid at 101, including an exit fee, a year ahead of the 2027 maturity. This is another example of how our focused structuring capabilities, patience, collaboration with management teams, and discipline yielded a positive outcome for OCSL stakeholders. Turning to non-accruals, at September 30th, six companies were on non-accord, the same as last quarter and down from 10 a year ago. Non-accruals represented approximately 1.8% of the total debt portfolio at fair value. This also represents 4% of total debt at cost, which is down 20 basis points sequentially and 250 basis points from a year ago on a cost basis. One investment came off non-accrule, one new tranche in an existing non- accrual name was added, and one new borrower was added. Baymark came off non-accrual following the resolution by lenders to recapitalize and stabilize the business. We added the first out-term loan of Pluralsight to non- accrual as the company continues to underperform expectations. As a reminder, in December 2025, we placed a second out- term loan on non-acrual and marked our equity to zero. The new name added to non accruals during this quarter is BioXL Therapeutics, a publicly traded bio-pharmaceutical company, but we expect a relatively quick resolution in the December quarter. BioXL entered Chapter 11 in late August 2026, with an up to $125 million stocking horse proposal from Teva, a large global pharmaceutical company. It was a fast-moving, court-supervised process, and in late October, the sale to Teva closed at a value in line with our carrying mark of $83 million. TEVA funded $57.5 million upfront at closing with a balance payable upon certain regulatory and commercial thresholds. We're pleased to say that on November 13, TEVA received FDA approval for Bio-X-Seltzer drug which has triggered the full $67.5 additional milestone to the lenders. This is expected to be paid within 30 days and will lead to a realized value well in excess of our carrying mark. Closing out the discussion on non-accruals is an update on PRAZIO. As a reminder, last quarter, 80% of the debt was paid down and the small amount that remained was returned to accrual status. In early November, the balance was fully paid down at par. Looking at total portfolio metrics as of September 30th, 79.1% of portfolio at fair value was first lien senior secured debt. Weighted average yield on debt investments was 9.4%, compared with 9.3% last quarter. The portfolio remains well diversified, with 170 portfolio companies. The average debt position is approximately 62 basis points of the total portfolio at fair value, and no single position exceeds 2.1%. percent. The median EBITDA for portfolio companies was approximately 180 million dollars. Portfolio company weighted average leverage was 5.1 times and the interest coverage was 2.3 times. Both metrics steady sequentially and compared to a year ago. On software, based on GIC's industry group classification, software represents 20 percent of the portfolio at fair value. Steady sequentially and down from 24% a year ago. 94% of our software positions are first lien, and ARR-based loans represent just 0.8% of the portfolio. Our high ARR risk software exposure remains relatively unchanged at approximately 3% of the performing debt portfolio. And with that, I'll turn the call over to Chris to review our financial results. Thank you, Raghav. In our fourth fiscal quarter ended September 30, 2026, adjusted total investment income was $68.0 million, down from $69.2 million in the prior quarter. The sequential decrease primarily reflected a lower average portfolio balance. Fiscal year adjusted total investment income was 281.4 million, compared with 315.4 million in the prior year. The year-over-year decrease was primarily attributable to lower reference rates and a lower average portfolio balance. We delivered adjusted net investment income of $29.6 million, or $0.34 per share, compared with $32.2 million, or $0.37 per share in the prior quarter. The sequential decline was driven by lower total investment income and a higher income-based or Part 1 incentive fee, partially offset by lower interest and other expenses. For the full year, adjusted net investment income was $131.7 million for $1.49 per share, compared with $151 million for $176 per share in fiscal 2025, with similar performance drivers as the quarterly results. On the incentive fee, we paid $4.8 million this quarter for approximately $0.05 per share compared with $2.4 million last quarter for $0,03 per share. A full quarterly incentive fee would have been approximately $6.0 million. So our total return hurdle reduced the fee by approximately $1.2 million, or about one cent per share in the September quarter. For the full year, incentive fee paid was $8.4 million, for 10 cents per share. Over the last year, our total returned hurdle reduced incentive fees by $16.1 million. We believe the mechanism is working as designed, aligning the fees Oak Tree earns with the total returns shareholders receive. Beginning in the December quarter, the September rate hike will start to flow through to net investment income. With 91% of our debt investments floating rate and 100% of out debt floating or swapped to floating, the net impact is positive, all else equal. Although resets are somewhat staggered across the portfolio, we'll see the majority of the impact in our December quarter earnings, with the full effect building from there. Once fully reset, every 25 basis point increase in base rates adds a little over half a penny per share per quarter to adjusted net investment income, with a little over $0.02 per share annualized. Turning to NAV, NAV per share was $15.63 as of September 30th, down 0.4% from $15 and 70 cents in June. PIC income represented approximately 7.3% of adjusted total investment income during the quarter, down from 7.8% last quarter. Approximately 75% of total PIC relates to investments that were structured with the option to PIC at origination. Investments generating non-cash income during the quarter are marked at a weighted average fair value of approximately 98. Our net leverage at quarter end was 1.00 times compared with 1.02 times last quarter and 0.97 times a year ago. Our long-term target leverage range of 0.9 times to 1.25 times remains unchanged. Total debt outstanding at quarter-end was $1.42 billion. As of September 30th, the weighted average interest rate on debt outstanding was 6.2% with 5.9% last quarter and 6.5% a year ago. Adjusted for the new 2031 notes, pay down of the 2027 notes and the higher base rate pro forma interest rate on debt is 6.4%. Unsecured debt represented approximately 88% of total debt at quarter end compared with 65% last-quarter and 64% a-year ago. for the expected repayment of the 2027 notes unsecured debt would have been approximately 64 percent of total debt at quarter end our liquidity was approximately 1.04 billion dollars including 45 million of cash and 994 million of undrawn capacity under our credit facilities pro forma for the repayment the 20 27 notes of maturity liquidity would have have been approximately $689 million, compared with $699 million last quarter and $695 million a year ago. Unfunded commitments, excluding those related to the joint ventures, were approximately $226 million. Ending with our joint venturers, together the JVs held approximately $547 million of investments across 144 portfolio companies and generated aggregate returns on equity of approximately 11.5% during the quarter. Leverage at the JVs was 2.0 times compared to 2.1 times last quarter. With that, I'll turn the call back to the operator for Q&A. We will now begin the question and answer session. If you would like to ask a question, please press star 1 to raise your hand. To withdraw your question, press star one again. We ask that you pick up your handset when asking a question to allow for optimum sound quality. If you are muted locally, please remember to unmute your device. Please stand by while we compile the Q&A roster. We have no questions at this time. I will now turn the call back to Allison for closing opening the line again i would like to reprompt for questions if you would like to ask a question please press star 1 to raise your hand to withdraw your question press star one again thank you please stand by Your first question comes from the line of Sean Paul Adams with D. Reilly Securities. Your line is open. Please go ahead. It looks like PIC kind of trended down a little bit since the June quarter. Was that due to the restructuring, or can you guys just walk me through the portfolio changes? Hey, Sean Paul, it's Chris. Thanks for the question. Yeah, in terms of the downtick quarter-on-quarter, you know, as mentioned in the prepared remarks, we did move BioXcel to non-accruals. That was part of the impact. We do expect a quick resolution there. And then the other factor, we had a royalty interest that had been picking previously that we exited during the quarter. Those were the two big drivers. Got it. Thank you for the call. Your next question comes from the line of Ethan K. with Lucid Capital Markets. Your line is open. Please go ahead. Hey, guys, just a quick one for me. Can you just kind of review capital allocation priorities? You talked about, you know, you have some room to kind of bring leverage higher if you want. You talked About remaining kind of flexible in the balance sheet, but just walk through, you know, balancing kind of deployment and repurchases and leverage, et cetera. Thanks very much. Hey, Ethan, it's Matt. Thanks for the question. So, you You know, we talk to the board every quarter about capital allocation and want to be thoughtful about it. You know. Since we took over management, we have not repurchased shares for a couple of reasons. I think the primary is just desire to have capital to continue to invest in portfolios and attractive loans that we see. That continues to be kind of priority number one. you know over over 2026 we ran leverage 0.97 to 1.07 you know as i mentioned the call our target is 0.9 to 1 0.25 um you know we we ended the year at one time so we definitely and as chris kind of walks through our our you know liquidity and capital we have we have plenty of capital so i think our our primary focus is to you know deploy and to attract investment opportunities we have capital you know we're comfortable taking our leverage up you know within within the range we've done in the last year you know 0.97107 so i think that's where we're going to be focused great and then i guess one more quick one um i think in the past you've kind of categorized you know the credits that have underperformed as maybe businesses that like struggled with you know, post-COVID normalization. You know, it looks like credit performance has stabilized nicely in the last couple of quarters. But curious if you kind of feel like the impact from that kind of trend has subsided largely, maybe, you know with the exception of Pluralsight. yeah hey sean uh hey ethan i can take that um uh so you're right like most of the the big declines uh in 21 and 22 were because of post-covid normalizations but also you know frankly a lot of the capital structures that were put in place in in 2021 and early 2022 were just not set up for base rates being low fours to five. So those were the primary reasons. I think going forward and what you're seeing right now is the non-accruals, the one non-acrual that was added, the new name, it's largely because of idiosyncratic reasons. So to give you some color, the name that was at it, it'S the largest opioid treatment center business in the US. So when you think about the end market, it' s not cyclical. And frankly, the revenues have not been cycling. They had an idiosyncratic issue in revenue collection because of bad ERP systems, which is what led to the restructuring. So when we see problems in the portfolio now, they're idiosyncratic as opposed to because of one big team. Great. Yeah, that was the crux of my question. Thanks very much. And I think, Ethan, just to follow up, you know, I do think, and we talked about the call, like the progress in BioAccel, I think you know I still think there's progress we can make on you know the existing NANUC rules. We have reached the end of the Q&A session. I will now turn the call back to Allison for closing remarks. Thank you all for joining us on today's call. Please feel free to reach out to me and the team with any questions. Have a great day, everyone. This concludes today's Call. Thank you for attending. You may now disconnect.

Company
OAKTREE SPECIALTY LENDING CORP
Keywords
OAKTREE SPECIALTY LENDING CORP